Deborah Honig
With Kinlytic proceeding so well, is there any chance of expanding the geography and indication of the current partner agreement prior to the formal FDA approval of the SBLA?
Cameron Groome
I'm going to go with another political answer on that one and say, yes. Yes, we are certainly looking at with our partner and certainly encouraging them to consider moving forward aggressively on both clinical label expansion, things like catheter prophylaxis, and the resuming systemic programs. But that's their funding decision at the end of the day. We're going to provide the best technical support we can, and certainly encourage them as we strongly believe in the clinical utility and clinical importance of the product as well as the economic -- very attractive economic drivers on that. Ken, what would you want to add to that?
Ken Hughes
Yes. There's absolutely no desire to stop after catheter clearance in the North American market. There's catheter clearance in Europe, there's catheter prophylaxis everywhere, and then there's the bigger indication, which are bigger markets for indications related to pulmonary embolism, like peripheral artery, locressive disease, stroke, even cancer indications associated with this product, and there's every intention to pursue all of these opportunities going forward.
Cameron Groome
Yes. So, we see Kinlytic very much as just an opportunity that continues to broaden and broaden both from clinical indications and geography. And I believe, we've said previously, we have had the European Medicines Agency reach out to Microbix and say, please don't forget about us. When you have a package to provide, we want to engage with you and see if this could be brought into Europe. Now, kinlytic was never approved in Europe, so it's not precisely the same pathway, as it would be in the United States and Canada, where it had been previously approved. But there's really been a tremendous openness on the part of the European regulators to engaging with us to see how it can be expeditiously brought into the European market, because there's a screaming need there as well.